Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study

ObjectiveWe conducted this multicenter retrospective study to evaluate the prevalence, clinical patterns, and risk factors for tigecycline-induced liver injury, which is a type of drug-induced liver injury (DILI).MethodsInpatients receiving intravenous tigecycline for ≥7 days were included. Patient information was collected to assess possible DILIs. The pattern and severity of tigecycline DILI were evaluated. A multivariable logistic regression model was used to identify the independent risk factors associated with tigecycline DILI.ResultsA total of 986 patients were identified and 397 patients were included in this study. The prevalence of tigecycline DILI was 10.3% (95% confidence interval [CI] = 7.51–13.7%). The most common type of tigecycline DILI was cholestatic, with mild severity observed in most cases. Abnormal baseline alanine aminotransferase levels (odds ratio [OR] = 3.11, 95% CI = 1.55–6.24, P = 0.001), intensive care unit admission (OR = 2.63, 95% CI = 1.32–5.36, P = 0.006), and treatment length (in weeks) (OR = 1.25, 95% CI = 1.05–1.49, P = 0.011) were independent risk factors for tigecycline DILI.ConclusionOur results indicate that the prevalence of tigecycline DILI is high, and that the patients at risk should receive special attention.